Research programme: antibacterial therapeutics - Advanced Life Sciences/University of British Columbia

Drug Profile

Research programme: antibacterial therapeutics - Advanced Life Sciences/University of British Columbia

Latest Information Update: 06 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of British Columbia
  • Developer Advanced Life Sciences; University of British Columbia
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Gram-negative infections; Gram-positive infections

Most Recent Events

  • 06 May 2011 Suspended for Gram-negative infections in Canada (unspecified route)
  • 06 May 2011 Suspended for Gram-positive infections in Canada (unspecified route)
  • 26 Jul 2010 Early research in Gram-positive infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top